{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:57:59Z","timestamp":1793408279364,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10157-025-02648-1","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:12:32Z","timestamp":1741065152000},"page":"1045-1052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of seroconversion rates after hepatitis B vaccination in patients with advanced chronic kidney disease and those receiving maintenance hemodialysis"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8143-8845","authenticated-orcid":false,"given":"Tomoyuki","family":"Fujikura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Katahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Iwakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naro","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2648_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S0272-6386(99)70312-4","volume":"33","author":"ER Miller","year":"1999","unstructured":"Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999;33:356\u201360.","journal-title":"Am J Kidney Dis."},{"key":"2648_CR2","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/ndt\/gfq499","volume":"26","author":"AE Grzegorzewska","year":"2011","unstructured":"Grzegorzewska AE, Kaczmarek-Leki V, M\u0142ot-Michalska M, et al. Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy. Nephrol Dial Transplant. 2011;26:970\u20136.","journal-title":"Nephrol Dial Transplant."},{"key":"2648_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1053\/j.ajkd.2016.03.424","volume":"68","author":"S Rhea","year":"2016","unstructured":"Rhea S, Moorman A, Pace R, et al. Hepatitis B reverse seroconversion and transmission in a hemodialysis center: A public health investigation and case report. Am J Kidney Dis. 2016;68:292\u20135.","journal-title":"Am J Kidney Dis."},{"key":"2648_CR4","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1681\/ASN.2021040432","volume":"32","author":"E Lacson","year":"2021","unstructured":"Lacson E, Argyropoulos C, Manley H, et al. Immunogenicity of SARS-CoV-2 vaccine in dialysis. J Am Soc Nephrol. 2021;32:2735\u201342.","journal-title":"J Am Soc Nephrol."},{"key":"2648_CR5","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.2215\/CJN.04670511","volume":"6","author":"NE Broeders","year":"2011","unstructured":"Broeders NE, Hombrouck A, Lemy A, et al. Influenza A\/H1N1 vaccine in patients treated by kidney transplant or dialysis: A cohort study. Clin J Am Soc Nephrol. 2011;6:2573\u20138.","journal-title":"Clin J Am Soc Nephrol."},{"key":"2648_CR6","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1053\/j.ajkd.2003.08.019","volume":"42","author":"G DaRoza","year":"2003","unstructured":"DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42:1184\u201392.","journal-title":"Am J Kidney Dis."},{"key":"2648_CR7","first-page":"527","volume":"17","author":"MH Ghadiani","year":"2012","unstructured":"Ghadiani MH, Besharati S, Mousavinasab N, et al. Response rates to HB vaccine in CKD stages 3\u20134 and hemodialysis patients. J Res Med Sci. 2012;17:527\u201333.","journal-title":"J Res Med Sci."},{"key":"2648_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1053\/j.ajkd.2019.06.014","volume":"75","author":"KM Krueger","year":"2020","unstructured":"Krueger KM, Ison MG, Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis. 2020;75:417\u201325.","journal-title":"Am J Kidney Dis."},{"key":"2648_CR9","doi-asserted-by":"publisher","first-page":"100775","DOI":"10.1016\/j.xkme.2023.100775","volume":"6","author":"R Sam","year":"2024","unstructured":"Sam R, Rankin L, Ulasi I, et al. Vaccination for patients receiving dialysis. Kidney Med. 2024;6:100775.","journal-title":"Kidney Med."},{"key":"2648_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJM198408233110803","volume":"311","author":"CE Stevens","year":"1984","unstructured":"Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis \u2014 immunogenicity and efficacy. N Engl J Med. 1984;311:496\u2013501.","journal-title":"N Engl J Med."},{"key":"2648_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.vaccine.2016.12.032","volume":"35","author":"E Zitt","year":"2017","unstructured":"Zitt E, Hafner-Giessauf H, Wimmer B, et al. Response to active hepatitis B vaccination and mortality in incident dialysis patients. Vaccine. 2017;35:814\u201320.","journal-title":"Vaccine."},{"key":"2648_CR12","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1016\/j.vaccine.2021.05.003","volume":"39","author":"AM Awad","year":"2021","unstructured":"Awad AM, Ntoso A, Connaire JJ, et al. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B\u00ae) in adults receiving hemodialysis. Vaccine. 2021;39:3346\u201352.","journal-title":"Vaccine."},{"key":"2648_CR13","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","volume":"31","author":"RS Janssen","year":"2013","unstructured":"Janssen RS, Mangoo-Karim R, Pergola PE, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine. 2013;31:5306\u201313.","journal-title":"Vaccine."},{"key":"2648_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis."},{"key":"2648_CR15","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1080\/21645515.2018.1452578","volume":"14","author":"H Kishino","year":"2018","unstructured":"Kishino H, Takahashi K, Sawata M, et al. Immunogenicity, safety, and tolerability of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young Japanese adults. Hum Vaccines Immunother. 2018;14:1773\u20138.","journal-title":"Hum Vaccines Immunother."},{"key":"2648_CR16","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","volume":"36","author":"S Jackson","year":"2018","unstructured":"Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018;36:668\u201374.","journal-title":"Vaccine."},{"issue":"Suppl 1","key":"2648_CR17","first-page":"S1","volume":"100","author":"U Krairittichai","year":"2017","unstructured":"Krairittichai U, Sethakarun S. A randomized controlled trial of seroconversion after 20 Mg versus 40 mg intramuscular hepatitis B virus vaccination in patients with chronic kidney disease stage 3. J Med Assoc Thail. 2017;100(Suppl 1):S1-7.","journal-title":"J Med Assoc Thail."},{"key":"2648_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/ndt\/gfac039","volume":"38","author":"HJ Manley","year":"2022","unstructured":"Manley HJ, Aweh G, Frament J, et al. A real world comparison of HepB (Engerix-B\u00ae) and HepB-CpG (Heplisav-B\u00ae) vaccine seroprotection in patients receiving maintenance dialysis. Nephrol Dial Transplant. 2022;38:447\u201354.","journal-title":"Nephrol Dial Transplant."},{"key":"2648_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-3083.1995.tb03626.x","volume":"42","author":"J Stachowski","year":"1995","unstructured":"Stachowski J, Kramer J, Fust G, et al. Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis Patients. Scand J Immunol. 1995;42:60\u20135.","journal-title":"Scand J Immunol."},{"key":"2648_CR20","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1016\/j.transproceed.2004.09.063","volume":"36","author":"FN Ozdemir","year":"2004","unstructured":"Ozdemir FN, Micozkadioglu H, Arat Z, et al. The importance of A3 allele in response to hepatitis B vaccine in end-stage renal disease patients. Transplant Proc. 2004;36:2615\u20137.","journal-title":"Transplant Proc."},{"key":"2648_CR21","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1016\/j.vaccine.2009.07.055","volume":"27","author":"B Afsar","year":"2009","unstructured":"Afsar B, Elsurer R, Eyileten T, et al. Antibody response following hepatitis B vaccination in dialysis patients: Does depression and life quality matter? Vaccine. 2009;27:5865\u20139.","journal-title":"Vaccine."},{"key":"2648_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/0886022X.2011.559300","volume":"33","author":"CM Brown","year":"2011","unstructured":"Brown CM, Donlon S, O\u2019Kelly P, et al. A prospective study of hepatitis B vaccination \u2013 A comparison of responders versus nonresponders. Ren Fail. 2011;33:276\u20139.","journal-title":"Ren Fail."},{"key":"2648_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2369-13-97","volume":"13","author":"S-Y Lin","year":"2012","unstructured":"Lin S-Y, Liu J-H, Wang S-M, et al. Association of response to hepatitis B vaccination and survival in dialysis patients. BMC Nephrol. 2012;13:97.","journal-title":"BMC Nephrol."},{"key":"2648_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/1319-2442.124572","volume":"25","author":"KA Saran","year":"2014","unstructured":"Saran KA, Sabry A, Halawany ZA, et al. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transplant. 2014;25:185\u201391.","journal-title":"Saudi J Kidney Dis Transplant."},{"key":"2648_CR25","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14760584.2016.1188697","volume":"15","author":"AE Grzegorzewska","year":"2016","unstructured":"Grzegorzewska AE, Swiderska MK, Warchol W. Antibodies to hepatitis B virus surface antigen and survival of hemodialysis patients \u2013 a prospective study. Expert Rev Vaccines. 2016;15:1063\u201374.","journal-title":"Expert Rev Vaccines."},{"key":"2648_CR26","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s11255-017-1616-9","volume":"49","author":"A Asan","year":"2017","unstructured":"Asan A, Demirhan H, Sorkun HC, et al. Factors affecting responsiveness to hepatitis B immunization in dialysis patients. Int Urol Nephrol. 2017;49:1845\u201350.","journal-title":"Int Urol Nephrol."},{"key":"2648_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s10157-018-1676-x","volume":"23","author":"HI Erdogdu","year":"2019","unstructured":"Erdogdu HI, Atalay E, Gursoy G, et al. Factors affecting inadequate response to HBV vaccine in hemodialysis patients: northeast Anatolia survey with six hemodialysis centers. Clin Exp Nephrol. 2019;23:530\u20136.","journal-title":"Clin Exp Nephrol."}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02648-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02648-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02648-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T06:54:49Z","timestamp":1757141689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02648-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2648"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02648-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at Hamamatsu University School of Medicine (Approval no. 23-290) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}